Krystal Biotech reports FY2022 net loss $140M; B-VEC PDUFA date May 19, 2023

Krystal Biotech, Inc.

2021-FY EPS reported -$5.49

Cash, cash equivalents and investments $383.8M at Dec 31, 2022.
Net loss $140.0M for FY2022 vs $69.6M in FY2021; diluted EPS $(5.49) vs $(3.13).
B-VEC PDUFA date set for May 19, 2023; all FDA inspections complete.
Phase 3 GEM-3 trial results for B-VEC published in New England Journal of Medicine.
Plans to initiate four pipeline trials in 2023 across dermatology, respiratory, aesthetics.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 1.0

Krystal Biotech, Inc. reported the fourth quarter ended December 31, 2022 results: net income $32.1 million, EPS $(1.25).

Period: the fourth quarter ended December 31, 2022
Net income: $32.1 million
EPS: $(1.25)
Result: reported results

Exact text from the filing

Net losses for the quarters ended December 31, 2022 and 2021 were $32.1 million and $21.8 million, or $(1.25) and $(0.94) respectively, per common share (basic and diluted).

View on SEC.gov

Earnings Releases SEC 8-K Item 2.02 confidence 1.0

Krystal Biotech, Inc. reported the year ended December 31, 2022 results: net income $140.0 million, EPS $(5.49).

Period: the year ended December 31, 2022
Net income: $140.0 million
EPS: $(5.49)
Result: reported results

Exact text from the filing

Net losses for the years ended December 31, 2022 and 2021 were $140.0 million and $69.6 million, or $(5.49) and $(3.13), respectively, per common share (basic and diluted).

View on SEC.gov

Browse all earnings releases →

Krystal Biotech, Inc. filing history →

Source: SEC EDGAR

accession 0001711279-23-000010

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.